Literature DB >> 15874846

Radical parametrectomy for occult cervical carcinoma detected posthysterectomy.

Jorge R Gori1, Heriberto G Fritsches, Roberto Castanño, Mariano Toziano, Diego Habich.   

Abstract

OBJECTIVE: There are no randomized studies of the two therapeutic alternatives (surgery or radiotherapy) for occult cervical carcinoma, and survival rates in the absence of residual cancer seem to be similar for both. This article presents our experience with radical reoperation for occult cervical carcinoma.
MATERIALS AND METHODS: Eleven patients with occult cervical cancer, primary invasive tumor >/=0.5 cm and </=3.0 cm, free margins in the hysterectomy specimen, and absence of clinically evident residual tumor were reoperated (radical parametrectomy with partial colpectomy and pelvic lymphadenectomy).
RESULTS: Histopathologic examination after reoperation showed no evidence of residual disease in nine cases and metastasis in lymph nodes in two cases, one of them with parametrial involvement. Survival was 100% among disease-free cases on reoperation and 0% in cases with residual disease (5-year follow-up).
CONCLUSIONS: Radical reoperation allows disease staging, sorting of patients into risk groups, and avoidance of radiation therapy in more than two thirds of the cases of occult cervical carcinoma.

Entities:  

Year:  2004        PMID: 15874846     DOI: 10.1097/00128360-200404000-00004

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  2 in total

1.  Occult invasive cervical cancer after simple hysterectomy: a multi-center retrospective study of 89 cases.

Authors:  Huimin Bai; Dongyan Cao; Fang Yuan; Huilan Wang; Jie Chen; Yue Wang; Keng Shen; Zhenyu Zhang
Journal:  BMC Cancer       Date:  2016-07-20       Impact factor: 4.430

2.  A comparison of laparoscopic and abdominal radical parametrectomy for cervical or vaginal apex carcinoma and stage II endometrial cancer after hysterectomy.

Authors:  Hongyuan Jiang; Lianxi Qu; Xishi Liu; Keqin Hua; Huan Xu; Sun-Wei Guo
Journal:  JSLS       Date:  2013 Apr-Jun       Impact factor: 2.172

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.